Where can I learn more about this study?
You can find more information about this study on the websites listed below. When a full report
of the study results is available, it can also be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT02983799”
into the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type “D0816L00003”
into the search box, and click “Find a Study”.
Full Study Title: Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a
Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed,
High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal
Cancer That Have Received at Least 1 Prior Line of Chemotherapy (LIGHT Study)
AstraZeneca Protocol Number: D0816L00003
National Clinical Trials Number: NCT02983799
AstraZeneca sponsored this study and has its headquarters in Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer important
health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_12_09
12 | Clinical Study Results